Login to Your Account



Financings Roundup

GenKyoTex's $20.4M Series C Funds NOX Inhibitor Progress

By Nuala Moran


Wednesday, May 25, 2011
LONDON – GenKyoTex SA has raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver clinical proof of concept for the company's NOX enzyme inhibition technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription